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Objectives We review our experience with transapical transcatheter aortic valve implantation (AVI) in patients with function-
ing mitral prostheses, and describe the technical considerations.
Background Transcatheter AVI for aortic stenosis in patients with mitral prostheses is technically challenging.
Methods Ten patients (7 mechanical and 3 bioprosthetic mitral valves) received the Edwards SAPIEN balloon-expandable
valve (Edwards Lifesciences, Irvine, California) during 2006 to 2010. All patients were declined conventional sur-
gery and prospectively followed. The mean patient age was 77.6  7.1 years (range: 67 to 88 years). The logis-
tic EuroSCORE and the Society of Thoracic Surgeons–predicted operative mortality were 30.3  18.6% (range:
11.4% to 70.4%), and 9.9  4.8% (range: 4.6% to 18.7%), respectively.
Results All valves were successfully implanted, with no 30-day mortality or mitral prosthetic dysfunction. Nine pa-
tients had none to mild residual aortic paravalvular leak. The overall survival was 60% at a mean follow-up
of 12.2  10.4 months (range: 2 to 33 months), with 4 nonvalve-related deaths. Seven patients improved
to New York Heart Association functional class I to II. The mean transvalvular gradient and effective orifice
area improved from 40.0  17.4 mm Hg to 8.2  2.1 mm Hg, and 0.6  0.1 cm2 to 1.3  0.2 cm2, re-
spectively (p  0.0001). The mitral bioprosthetic strut predisposes to device “shift” during deployment. An
“unfavorable” mechanical mitral prosthetic cage or pivot strut can also cause shifts. Balloon shifts during
valvuloplasty warn of a high likelihood of prosthesis shift.
Conclusions This report details the technical lessons learned thus far from our first 10 patients. Excellent procedural success
and early outcomes in patients with functioning mitral prosthesis can be achieved. (J Am Coll Cardiol 2011;58:
715–21) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.04.023Transapical transcatheter aortic valve implantation (AVI)
for aortic stenosis and transcatheter valve-in-valve implan-
tation for failed aortic bioprostheses have been described
using the Edwards SAPIEN balloon expandable valve
(Edwards Lifesciences) (1,2). The PARTNER (Placement
of AoRTic TraNscathetER Valves) trial demonstrated sig-
nificantly reduced mortality, rehospitalization rates and
symptoms, in nonsurgical patients undergoing transfemoral
AVI, despite the higher incidence of major strokes and
vascular events (3). Transcatheter AVI may also be benefi-
cial in the elderly with previous coronary bypass and mitral
valve replacement. The latter is, however, technically chal-
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accepted April 19, 2011.lenging. We report our transapical AVI experience in
patients with functioning mitral prosthesis and highlight
the technical considerations learned.
Methods
Ten patients with functioning mitral prostheses underwent
transapical AVI for severe symptomatic aortic stenosis using
the SAPIEN balloon-expandable bioprosthesis between
June 2006 and July 2010. The prosthesis was approved for
compassionate use by the department of Health and Wel-
fare, Ottawa, Canada, in consenting patients declined for
conventional reoperative surgery. All patients were prospec-
tively followed. Statistical analysis was performed using
SPSS version 18.0 for Windows (SPSS, Chicago, Illinois).
Paired Student t test was used to analyze continuous data,
and values were expressed as mean  SD.
The transapical AVI performed through a 4- to 5-cm left
anterolateral mini-thoracotomy has been previously described
(4,5). Rapid ventricular pacing (160 to 200 beats/min) was
used during balloon valvuloplasty and valve deployment. Bal-
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tional role to assess the degree of
balloon contact with the mitral
prosthetic cage or struts; and to
observe balloon displacement dur-
ing inflation. A shorter 3-cm val-
vuloplasty balloon similar to the
Ascendra balloon catheter (Ed-
wards Lifesciences) is used to sim-
ulate and predict balloon displace-
ment during valve deployment.
Results
The mean patient age was 77.6  7.1 years (range 67 to 88
ears). Seven patients were female. Table 1 summarizes the
aseline characteristics of all patients. Three patients had
ndergone 2 previous operations: 1) subaortic myomectomy
years before concomitant mitral valve replacement and
oronary bypass; 2) mitral paravalvular leak repair following
itral valve replacement; and 3) mitral valve re-replacement
-years post-initial operation, respectively. The mean inter-
al between AVI and the most recent operation was 11.7 
.2 years (range: 4 to 19 years). The mean transmitral pros-
hetic gradient was 5.7 2.5 mm Hg (range: 2 to 10 mm Hg).
Three patients were morbidly obese (body mass index
30 kg/m2). The mean pre-procedural pulmonary artery
ystolic pressure was 54.8  18.8 mm Hg (range: 33 to 100
mm Hg), with 4 patients having pulmonary hypertension
(60 mm Hg). Six patients had permanent pacemakers
pre-AVI. Two patients had coronary angioplasty within 30
days of AVI, 1 for acute coronary syndrome during the same
admission. One patient required short-term dialysis follow-
ing screening angiography, and another had survived a failed
attempt at transfemoral AVI with distal valve embolization
4 years earlier.
Abbreviations
and Acronyms
AR  aortic regurgitation
AVI  aortic valve
implantation
LVEF  left ventricular
ejection fraction
LVOT  left ventricular
outflow tract
NYHA  New York Heart
Association
Baseline Pre-Operative Patient CharacteristicsTable 1 Baseline Pre-Operative Patient Characteristics
Patient # Age, yrs Sex
LVEF
(%)
PASP
(mm Hg)
STS
Score
Logistic
EuroSCORE Past Cardiac
1 86 F 60 61 18.7 70.43 MVR  CABG
myomectom
2 82 F 60 48 13.8 30.53 MVR
3 78 M 40 63 5.0 32.62 MVR  AF abl
4 67 M 50 60 4.6 13.27 MVR  CABG
5 77 F 60 33 8.2 16.13 MVR
6 71 F 60 41 4.6 11.42 MVRTVA
7 82 F 35 40 8.9 13.03 MVRTVR
8 69 F 50 100 10.3 31.91 MVR  CABG
 AF ablati
9 76 M 20 55 15.5 38.75 MVR  CABG
10 88 F 65 47 9.8 28.59 MVR  CABG
Patients 1–7: mechanical mitral prosthesis; patients 8–10: bioprosthetic mitral valve. *Within 30
AF  atrial fibrillation; BAV  balloon aortic valvuloplasty; CABG  coronary artery bypass grafsystolic pressure; PCI  percutaneous coronary intervention; PPM  permanent pacemaker; Pre-Op  pre
valve annuloplasty; TVR  tricuspid valve replacement.The majority were in New York Heart Association
(NYHA) functional class IV (80%) (Online Table 1). The
mean left ventricular ejection fraction (LVEF) was 50 
14.3% (range: 20% to 65%). The mean aortic valve area was
0.6  0.1 cm2 (range: 0.5 to 0.8 cm2), with a mean
transaortic valvular pressure gradient of 38.5 17.1 mm Hg
(range: 20 to 70 mm Hg). Three patients had previous
balloon aortic valvuloplasty.
The logistic EuroSCORE and the Society of Thoracic
Surgeons predicted mortality were 30.3  18.6% (range:
11.4% to 70.4%), and 9.9  4.8% (range: 4.6% to 18.7%),
respectively. All valves were successfully implanted. The first
patient received a Cribier-Edwards valve (Edwards Life-
sciences), whereas the others received the Edwards SAPIEN
(9000TFX) valve. Table 2 summarizes the procedure and
outcomes. The first patient had a functioning Björk-Shiley
mechanical mitral prosthesis, whereas the following mitral
prostheses are represented in the others.
CarboMedics bileaflet mechanical valve. The patient had
a CarboMedics valve (Sorin, Milano, Italy) with rigid
housing cage and pivot guards within the cage. Despite a
bulky sewing cuff, the cuff was sewn above annulus, and the
cage is distant to the left ventricular outflow tract (LVOT)
and aortic annulus. Slight balloon displacement occurred
during valvuloplasty, but none during deployment of the
23-mm SAPIEN valve. There was only trivial paravalvular
aortic regurgitation (AR) (Online Fig. 1).
St. Jude Medical bileaflet mechanical valves. This me-
chanical valve (St. Jude Medical, Minneapolis, Minnesota)
has a rigid housing cage with pivot guards rising above the
cage. Four of 5 patients underwent uneventful AVI (Fig. 1).
In 1 patient, a 3-mm aortic shift occurred at the end of
balloon inflation during valve deployment, which resulted in
mild paravalvular AR. Subsequent review revealed that the
rigid housing cage sat below the mitral annulus and pro-
truded into the LVOT (Fig. 2).
tion
Years
Post-
Operation
Redo
Number
Prior
PCI
Prior
PPM
Prior
BAV Prior Stroke/TIA
Pre-Op
AF/Flutter
aortic 13 2 No Yes Yes Stroke/carotid
endarterectomy
Yes
9 1 No No No No Yes
13 2 Yes* Yes No No Yes
19 1 Yes No Yes No Yes
15 2 No Yes No No Yes
12 1 No No No TIA Yes
14 1 No Yes No No Yes
4 1 No Yes Yes Stroke Yes
8 1 Yes No No No Yes
10 1 Yes* Yes No No No
f transcatheter aortic valve implantation.
 left ventricular ejection fraction; MVR  mitral valve replacement; PASP  pulmonary arterialOpera
 Sub
y
ation
 TVA
 TVA
on
 TVA
days o
t; LVEF-operative; STS  Society of Thoracic Surgeons; TIA  transient ischemic attack; TVA  tricuspid
act.
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pericardial (Carpentier-Edwards Perimount valve) or por-
cine valves (Mosaic Valve, Medtronic) had the commissural
strut protruding into the LVOT, which caused significant
balloon displacement towards the aorta during inflation. All
transapical AVI was successful despite the displacements
(Fig. 3). One transfemoral AVI in a patient with a Mosaic
bioprosthesis failed due to gross balloon shift during de-
Figure 1 St. Jude Medical Mechanical Mitral Valve
(A) St. Jude Medical mechanical mitral valve. Arrow points to the mitral prosthetic
tic valvuloplasty, with reference to the red line. Arrow points to a nonmobile mitral p
thesis in situ (F). No paravalvular leak (G).
Procedural Considerations and OutcomeTable 2 Procedural Considerations and Outcome
Patient #
Mitral Prosthesis (Size)
Implant Year
Aortic
Annulus
(mm)
SAPIEN
Size
(mm)
Strut at
LVOT
Pro
R
at
1 Bjork-Shiley (27 mm) 1993 22 23 No
2 St. Jude (25 mm) 1999 22 26 No
3 St. Jude (27 mm) 1996 27 26 No
4 St. Jude (25 mm) 1990 24 26 No
5 St. Jude (27 mm) 1995 24 26 No
6 Carbomedic (25 mm) 1998 20 23 No
7 St. Jude 1996 22 23 No
8 Perimount (27 mm) 2005 19 23 Yes
9 Mosaic 2001 24 26 Yes
10 Mosaic 1999 25 26 Yes
Patients #1 to #7: mechanical mitral prosthesis; Patients #8 to #10: bioprosthetic mitral valve.
AR  aortic regurgitation; BAV  balloon aortic valvuloplasty; LVOT  left ventricular outflow trployment, and valve embolization (Fig. 4). She returned for
successful transapical AVI 4 years later (Fig. 5). A 26-mm
SAPIEN valve was positioned more ventricular (60% of the
stent in LVOT) in anticipation of the shift, and significant
countertraction on both the valve catheter and delivery
sheath was necessary to restrain the aortic shift.
Echocardiographic outcomes. Paravalvular AR was ab-
sent or mild in 8 of 10 patients. The possible causes of the
B). Root aortogram (C). Insignificant balloon shift aortic-ward during balloon aor-
ic leaflet during balloon inflation (D and E). Completion aortogram with SAPIEN pros-
BAV Shift Valve Shift
Paravalvular
AR Reinflation
Duration
to Death
(Days)
No No Mild No 861
No No None No
No No None No 245
No No Trivial No
2 mm ventricular 3 mm aortic Mild No
Yes No Trivial No 144
No No Mild No
Yes 1 mm aortic Moderate No 378
Yes 2 mm aortic Trivial No
Gross aortic 2 mm aortic Trivial Noring (
rosthetsthetic
ing
LVOT
Yes
No
No
No
Yes
No
No
No
No
No
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Transapical AVI Post-Mitral Replacement August 9, 2011:715–21moderate paravalvular AR in 2 patients are: 1) suboptimal
position due to balloon displacement during deployment;
and 2) insufficient oversizing of the selected transcatheter
valve (26-mm valve into a 26- to 27-mm aortic annulus).
The later patient did not have demonstrable paravalvular
AR 6 months later. The mean transvalvular pressure gradi-
ent and effective orifice area improved from 40.0  17.4
m Hg to 8.2  2.1 mm Hg, and 0.6  0.1 cm2 to 1.3 
.2 cm2, respectively (p  0.0001) (Online Table 1). The
itral prosthetic function remained unaffected in all pa-
ients. At a mean echocardiographic follow-up of 13.9 
.7 months (range: 6 to 27 months), there was no structural
alve deterioration or displacement.
linical outcomes. The mean procedural time was 97.0 
1.8 min (range: 83 to 121 min), with no intraoperative
ortality or complications. Two patients required subse-
uent left pleural drainage, 2 developed acute renal deteri-
ration not requiring dialysis, and 1 was successfully treated
or right heart failure. Post-procedural delirium was com-
on (50%). The mean blood transfusion requirement was
.8  1.2 U (range: 0 to 3 U). Two of 4 patients without
acemakers pre-AVI required new pacemakers post-AVI
Figure 2 St. Jude Mechanical Valve With Prominent Prosthetic
Arrow points to the mitral prosthetic ring below the mitral annulus (A). Root aorto
catheter (B). Ventricular shift of the balloon during balloon aortic valvuloplasty, wh
prosthesis (E to G). Mild paravalvular leak (H).or complete heart block. pThere was no 30-day mortality, and patients improved,
ith 70% in NYHA functional class I to II (Online Table 1).
t mean follow-up of 12.2  10.4 months (range: 2 to 33
onths), there were 4 nonvalve-related deaths (mean dura-
ion to demise was 407.0  317.5 days [range: 144 to 861
ays]), giving an overall survival of 60%. One patient died
rom a presumed ischemic bowel 2 years post-AVI,
hereas another succumbed to sepsis and renal failure 1
ear later. The third patient with initial moderate para-
alvular AR died 8 months post-AVI from nonvalve-
elated pulmonary failure. The last patient died from a
eparin-related bleeding complication during hip re-
lacement 5 months post-AVI. Our longest surviving
atient is now 2.5 years post-AVI.
iscussion
he technical concerns of implanting a SAPIEN valve in
atients with prosthetic mitral valves evolve around the
nteraction between both the aortic and mitral prosthesis at
he anatomic aortomitral continuity. Previous reports of
atients with functioning mechanical mitral prostheses em-
ith reference red line at the level of the base of the aortic sinuses and pigtail
erencing the red line to the balloon markers (C and D). Aortic shift of SAPIENRing
gram w
en refloyed the percutaneous retrograde approach using the
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transapical approach using the SAPIEN valve (7).
This present series demonstrates that the transapical AVI
of a balloon expandable valve is feasible and safe in patients
with both mechanical and bioprosthetic mitral prostheses.
Technical challenges however exist in patients with mitral
bioprostheses. Special procedural considerations are elaborated.
Type of mitral prosthesis. Mechanical valves have a rigid
housing cage, with or without protruding pivot guards
(Online Fig. 2). The St. Jude Medical valve has a narrow
housing cage. The CarboMedics valve has “hidden” pivot
guards within the solid housing. Both, however, have a
small degree of rigid cage protruding into their ventricular
aspect that may extend into the LVOT and cause balloon
displacement. In contrast, the On-X mechanical valve
(On-X Life Technologies, Austin, Texas) has a high, rigid
housing cage without protruding pivot guards. Foreseeably,
this may interfere with transapical AVI. Balloon valvulo-
plasty is mandatory to assess the degree of balloon displace-
ment if the transfemoral approach is considered. The
transapical approach is better and safer should significant
displacement occur.
Bioprostheses have more prominent commissural struts
Figure 3 Carpentier-Edwards Perimount Bioprosthetic Valve
(A) Carpentier-Edwards Perimount bioprosthetic valve. Arrow points to the mitral p
drawn arbitrarily at the level of the aortic leaflets, noting the relative paucity of lea
during deployment, but not obstructing the left main coronary ostia (E and F).and are invariably impinging on the LVOT. This causesballoon displacement toward the aorta during inflation,
with resultant valve malposition or embolization (Fig. 4).
The transapical approach is best suited for these patients
(Fig. 5).
Relationship between the aortic annulus and the mitral
prosthetic housing or bioprosthetic strut. Echocardio-
graphic assessment is crucial to determine: 1) the extent of
prosthetic housing/strut protrusion into the LVOT; 2) the
distance between the protruding rigid structure and the
aortic annulus; and 3) the location of the rigid housing in
relation to the mitral annulus. The short distance between
the protruding prosthetic housing/strut and the aortic an-
nulus increases the risk of balloon displacement. The
mechanical prostheses are generally less problematic because
of the absence of commissural struts. However, its housing
cage may be seated below the mitral annulus (within the
ventricle), due to an inverting suture technique. This pre-
disposes to balloon displacement, usually at the end of
balloon inflation (Fig. 2).
Balloon valvuloplasty. Balloon valvuloplasty allows for
observation of balloon “shifts” due to the rigid mitral
prosthetic housing or strut. Using a balloon similar to that
for subsequent prosthesis deployment provides the best
tic ring and strut extending into the left ventricular outflow tract (B). Red line
d annular calcification (C and D). A 1-mm SAPIEN prosthesis shift aortic-wardsrosthe
flet anprediction of the degree of balloon shift during actual
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imizes balloon displacement.
Valve positioning. Valve positioning should be adjusted
according to the degree of balloon displacement observed
during valvuloplasty. Generally, in patients without mitral
prostheses, the transapical valve is positioned at the aortic
annulus with 40% to 50% of its stent below the annulus. In
patients with mechanical mitral prostheses, the valve is
positioned more ventricular (50% to 60% of stent below the
annulus) to compensate for aortic displacement when val-
vuloplasty balloon shift is noted. With mitral bioprostheses,
balloon displacement always occurs despite excellent transapi-
cal stabilization. If gross aortic shift is anticipated, the valve is
positioned even more ventricular (60% of stent in LVOT).
Valve stabilization and deployment. The transapical oper-
ator can firmly stabilize both the delivery sheath and catheter
when anticipating aortic displacement. Slow balloon inflation
minimizes the displacement and also allows an experienced
operator to actively pull back the valve at the earliest sign of
balloon shift. The latter, however, also risks malposition and is
not recommended for inexperienced operators.
Other considerations. Aortic annulus measurement, valve
sizing, and other principles for SAPIEN transcatheter AVI
Figure 4 Mosaic Bioprosthetic Mitral Valve During Transfemora
Arrow points to the bioprosthetic strut in close proximity to the aortic annulus and
radiopaque tips of the bioprosthesis (B). Gross aortic shift of the SAPIEN prosthe
2 bioprosthetic tips (C to E). Embolized prosthesis subsequently secured in the aare similar to those previously described (1,4,8). Aggressivevalve oversizing may worsen deployment shifts. Redilation
for paravalvular leaks should be avoided because it may
displace the valve, and overdilation of the outflow stent
aggravates transvalvular regurgitation. We do not think that
there is an increased risk of coronary obstruction in these
patients, if these rules are heeded.
The 50% new pacemaker rate (2 of 4 patients without
pacemakers pre-AVI) appears high compared with patients
without mitral prosthesis, but the numbers are too small to
draw any conclusions. The overall survival of 60% at mean
duration of 12.2  10.4 months in this cohort is relatively
lower compared with our published 12-month survival rate of
71.9  5.5% (9).
Conclusions
Various degrees of balloon displacement occur due to impinge-
ment on the housing cage and pivot guards of mechanical
mitral valves and on the bioprosthetic struts. Optimal valve
position is achievable with experience and technical modifica-
tions. The high-risk patients have a bioprosthetic mitral valve,
mechanical valve cage seating below the mitral annulus, and/or
valvuloplasty shifts. The transapical approach is safe, with good
tic Valve Implantation
the left ventricular outflow tract (A). Root aortogram showing only the
row points to the ventricular marker of the balloon and red line between
rch (F).l Aor
within
sis. Ar
ortic aoutcomes in patients with mitral prostheses.
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